Advanced search
Publication Cover
Renal Failure Volume 27, 2005 - Issue 1
Submit an article Journal homepage
4,682
Views
41
CrossRef citations to date
0
Altmetric
Clinical Study

Lercanidipine in Patients with Chronic Renal Failure: The ZAFRA Study

Dr. Niclás Roberto Robles Unidad de HTA, Hospital Infanta Cristina, Carretera de Portugal s/n, Badajoz, 06080, Spain; Unidad de HTA, Hospital Infanta Cristina, Carretera de Portugal s/n, Badajoz, 06080, Spain
,
J Ocon Fundación Puigvert, Barcelona, Spain
,
C F Gomez Hospital Gregorio Marañón, Madrid, Spain
,
M Manjon Hospital Clínico, Granada, Spain
,
L Pastor Hospital Miguel Servet, Zaragoza, Spain
,
J Herrera Hospital General de Asturias, Oviedo, Spain
,
J Villatoro Hospital General de Castellón, Castellón de la Plana, Spain
,
J Calls Hospital Fundación de Manacor, Menorca, Spain
,
J Torrijos Hospital Fundación de Manacor, Menorca, Spain
,
V I Rodríguez Hospital Severo Ochoa, Madrid, Leganes, Spain
,
M M. A Rodriguez Hospital La Inmaculada, Huercal-Overa, Almeria, Spain
,
M L Mendez Hospital Nuestra Señora de la Candelaria, Tenerife, Spain
,
A Morey Clinica Miramar, Barcelona, Spain
,
F I Martinez Hospital de Galdacano, Bilbao, Spain
,
J Marco Hospital Son Dureta, Mallorca, Spain
,
A Liebana Hospital Ciudad de Jaen, Jaen, Spain
,
B Rincon Hospital Virgen de la Luz, Cuenca, Spain
&
F Tornero Hospital Virgen de la Luz, Cuenca, Spain
 show all
Pages 73-80 | Published online: 07 Jul 2009

Citations (41)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (17)

Kai-Hung Cheng, Kai-Chun Cheng, Kai-Yuan Cheng, Yi-Hsin Yang, Chung-Wei Lee & Wen-Ter Lai. (2017) Long-term outcomes of lercanidipine versus other calcium channel blockers in newly diagnosed hypertension: a nationwide cohort study. Current Medical Research and Opinion 33:6, pages 1111-1117.
Read now
Christina Antza, Stella Stabouli & Vasilios Kotsis. (2016) Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence. Vascular Health and Risk Management 12, pages 443-451.
Read now
Costas Tsioufis, Kyriakos Dimitriadis, Emmanouil Mantzouranis, Ilianna Mani & Dimitrios Tousoulis. (2016) Differential effects of lercanidipine/enalapril versus amlodipine/enalapril and hydrochlorothiazide/enalapril on target organ damage and sympathetic activation in non-obese essential hypertensive subjects. Current Medical Research and Opinion 32:sup2, pages 35-41.
Read now
Nicolas Roberto Robles, Carlos Calvo, Javier Sobrino, Eugenia Espinel, Rafael Esteban, Lourdes Mateos & Juan F Macias. (2016) Lercanidipine valuable effect on urine protein losses: the RED LEVEL study. Current Medical Research and Opinion 32:sup2, pages 29-34.
Read now
Emiliano Angeloni, Angelo Vitaterna, Paola Lombardo, Michele Pirelli & Simone Refice. (2015) Single-pill combination therapy in the initial treatment of marked hypertension: a propensity-matched analysis. Clinical and Experimental Hypertension 37:5, pages 404-410.
Read now
Meng Peng, Xiong-jing Jiang, Hui Dong, Yu-bao Zou, Hui-min Zhang, Hai-ying Wu & Yuejin Yang. (2015) Can lercanidipine improve renal function in patients with atherosclerotic renal artery stenosis undergoing renal artery intervention?. Current Medical Research and Opinion 31:1, pages 177-182.
Read now
Michel Burnier. (2013) Renal protection with calcium antagonists: the role of lercanidipine. Current Medical Research and Opinion 29:12, pages 1727-1735.
Read now
Claudio Borghi & Francesca Santi. (2012) Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence. Patient Preference and Adherence 6, pages 449-455.
Read now
Carlos Escobar, Rocio Echarri & Vivencio Barrios. (2012) Emerging drug combinations to optimize renovascular protection and blood pressure goals. International Journal of Nephrology and Renovascular Disease 5, pages 69-80.
Read now
N.R. Robles, B. Romero, E. Garcia de Vinuesa, E. Sánchez-Casado & J.J. Cubero. (2010) Treatment of Proteinuria with Lercanidipine Associated with Renin-Angiotensin Axis-Blocking Drugs. Renal Failure 32:2, pages 192-197.
Read now
Christos Chatzikyrkou, Hermann Haller & Jan Menne. (2009) The role of fixed-dose combinations in the management of hypertension: focus on lercanidipine-enalapril. Expert Opinion on Pharmacotherapy 10:11, pages 1833-1840.
Read now
Menno T Pruijm, Marc P Maillard & Michel Burnier. (2008) Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine. Vascular Health and Risk Management 4:6, pages 1159-1166.
Read now
Vivencio Barrios, Carlos Escobar & Rocio Echarri. (2008) Fixed combinations in the management of hypertension: perspectives on lercanidipine – enalapril. Vascular Health and Risk Management 4:4, pages 847-853.
Read now
Francisco Javier Martinez-Martin & Margarita Saiz-Satjes. (2008) Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study. Expert Review of Cardiovascular Therapy 6:10, pages 1347-1355.
Read now
Nicolás Roberto Robles. (2008) Calcium Antagonists and Renal Failure Progression. Renal Failure 30:3, pages 247-255.
Read now
C Venkata S Ram. (2006) Hypertension, possible vascular protection and lercanidipine. Expert Review of Cardiovascular Therapy 4:6, pages 783-788.
Read now
Claudio Borghi. (2005) Lercanidipine in Hypertension. Vascular Health and Risk Management 1:3, pages 173-182.
Read now

Articles from other publishers (24)

Joanna Hajdys, Piotr Fularski, Klaudia Leszto, Gabriela Majchrowicz, Magdalena Stabrawa, Ewelina Młynarska, Jacek Rysz & Beata Franczyk. (2023) New Insights into the Nephroprotective Potential of Lercanidipine. International Journal of Molecular Sciences 24:18, pages 14048.
Crossref
Muhammet Yusuf Tepebaşı, Jale Selli, Salih Gül, İbrahim Hüseynov, Adem Milletsever & Esma Selçuk. (2023) Lercanidipine alleviates doxorubicin-induced lung injury by regulating PERK/CHOP and Bax/Bcl 2/Cyt c pathways. Histochemistry and Cell Biology.
Crossref
Alexander Schütze, Peter Benöhr, Marion Haubitz, Roland Radziwill & Carina Hohmann. (2023) Development of a list with renally relevant drugs as a tool to increase medicines optimisation in patients with chronic kidney disease. European Journal of Hospital Pharmacy 30:1, pages 46-52.
Crossref
İlter İLHAN, Halil AŞCI, Mehmer Abdulkadir SEVÜK, Orhan Berk İMECİ, Adem MİLLETSEVER & Okan SANCER. (2022) DOKSORUBİSİN İLE OLUŞTURULAN BÖBREK HASARINDA LERKANİDİPİNİN ANTİOKSİDAN VE ANTİAPOPTOTİK ETKİLERİNİN BCL-2/BAX/SİT C/ CAS-3 YOLAĞI ÜZERİNDEN ARAŞTIRILMASIINVESTIGATION OF ANTIOXIDANT AND ANTIAPOPTOTIC EFFECTS OF LERCANIDIPINE IN DOXORUBICIN-INDUCED KIDNEY DAMAGE VIA BCL-2/BAX/SIT C/CAS-3 SIGNALING PATHWAY. SDÜ Tıp Fakültesi Dergisi 29:4, pages 671-679.
Crossref
Marina G. Bubnova. (2022) Optimizing therapy for cardiovascular diseases: proven organ-protective and preventive effects of pitavastatin and lercanidipine: A review. CardioSomatics 13:1, pages 31-42.
Crossref
O. B. Kuzmin, V. V. Zhezha & V. V. Belyanin. (2021) Dihydropyridine calcium channel blockers for the renoprotective therapy of hypertensive patients with chronic kidney disease. Nephrology (Saint-Petersburg) 25:2, pages 27-34.
Crossref
Giuseppe Mancia & Kostantinos Tsioufis. (2019) Current perspective on the use of calcium channel blockers to treat hypertensive patients: the role of lercanidipine. Future Cardiology 15:4, pages 259-266.
Crossref
O D Ostroumova, V V Vikentev, A G Abrosimov & E A Smoliarchuk. (2017) Dihydropyridine calcium antagonists: conscious choice. Systemic Hypertension 14:1, pages 61-68.
Crossref
Nicolás R Robles, Francesco Fici & Guido Grassi. (2016) Dihydropyridine calcium channel blockers and renal disease. Hypertension Research 40:1, pages 21-28.
Crossref
O D Ostroumova, A A Zykova & M L Maksimov. (2016) Nephroprotective in patients with metabolic syndrome: approaches to the appointment of antihypertensive drugs. Systemic Hypertension 13:2, pages 77-83.
Crossref
A G Evdokimova, Yu V Ryzhova & L V Gukolenko. (2016) CLINICAL EFFECTS AND RENOPROTECTIVE FACILITIES OF OLMESARTAN AND LERKANIDIPINEAS MONOTHERAPY AND WHEN COMBINED APPLICATION IN PATIENTS WITH ARTERIAL HYPERTENSION. Journal of Clinical Practice 7:1, pages 11-21.
Crossref
G S Anikin. (2014) Pleiotropic features of dihydropyridine calcium channel antagonists. Systemic Hypertension 11:3, pages 81-83.
Crossref
G. G Shehyan, A. A Yalymov, V. S Zadionchenko & S. I Varentsov. (2014) Application of lercanidipine in the treatment of hypertension. CardioSomatics 5:2, pages 46-50.
Crossref
G. A Baryshnikova, S. A Chorbinskaya & I. I Stepanova. (2014) Calcium antagonist lercanidipine in hypertension. CardioSomatics 5:1, pages 9-15.
Crossref
L. O. Minushkina. (2013) COMBINATION THERAPY IN THE MANAGEMENT OF ARTERIAL HYPERTENSION: EFFECTIVENESS OF THE LERCANIDIPINE AND ENALAPRIL COMBINATION. Cardiovascular Therapy and Prevention 12:5, pages 75-80.
Crossref
Viktor Viktorovich Fomin & Sergey Valentinovich Moiseev. (2013) Sovershenstvovanie podkhodov k primeneniyu antagonistov kal'tsiya: fokus na lerkanidipin. CardioSomatics 4:3, pages 42-45.
Crossref
Nicolás R. Robles & Roman Hernandez-Gallego. (2012) Blood Pressure in Renal Disease: How to Accomplish the Goal?. Cardiovascular Therapeutics 30:4, pages 193-198.
Crossref
N. R. Robles, B. Romero, E. Garcia de Vinuesa, E. Sánchez-Casado & J. J. Cubero. (2011) Treatment of proteinuria with lercanidipine associated with reninangiotensin axis-blocking drugs. Cardiovascular Therapy and Prevention 10:3, pages 83-88.
Crossref
Claudio Borghi & Arrigo F. G. Cicero. (2012) Rationale for the Use of a Fixed-Dose Combination in the Management of Hypertension. Clinical Drug Investigation 30:12, pages 843-854.
Crossref
Christos ChatzikyrkouHermann HallerJan Menne. (2009) Fixed-dose combination of lercanidipine/enalapril in the treatment of hypertension in the elderly. Aging Health 5:2, pages 141-149.
Crossref
Christos ChatzikyrkouHermann HallerJan Menne. (2009) Efficacy and safety of fixed-dose Lercanidipine-Enalapril for the treatment of hypertension. Clinical Medicine. Therapeutics 1, pages CMT.S2315.
Crossref
V. Barrios, C. Escobar, M. De La Figuera, J. Honorato, J. L. Llisterri, J. Segura & A. Calderón. (2008) High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study. International Journal of Clinical Practice 62:5, pages 723-728.
Crossref
A.P. Maggioni, M.G. Franzosi & R. Latini. 2008. A worldwide yearly survey of new data and trends in adverse drug reactions and interactions. A worldwide yearly survey of new data and trends in adverse drug reactions and interactions 223 230 .
Cherylyn Beckey, Amber Lundy & Nahla Lutfi. (2016) Lercanidipine in the Treatment of Hypertension. Annals of Pharmacotherapy 41:3, pages 465-474.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.